A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study

C. A. Drukker, J. M. Bueno-De-Mesquita, V. P. Retèl, W. H. Van Harten, H. Van Tinteren, J. Wesseling, R. M.H. Roumen, M. Knauer, L. J. Van 'T Veer, G. S. Sonke, E. J.T. Rutgers, M. J. Van De Vijver, S. C. Linn

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

174 Citaten (Scopus)


The 70-gene signature (MammaPrint™) has been developed on retrospective series of breast cancer patients to predict the risk of breast cancer distant metastases. The microarRAy-prognoSTics-in-breast-cancER (RASTER) study was the first study designed to prospectively evaluate the performance of the 70-gene signature, which result was available for 427 patients (cT1-3N0M0). Adjuvant systemic treatment decisions were based on the Dutch CBO 2004 guidelines, the 70-gene signature and doctors' and patients' preferences. Five-year distant-recurrence-free-interval (DRFI) probabilities were compared between subgroups based on the 70-gene signature and Adjuvant! Online (AOL) (10-year survival probability <90% was defined as high-risk). Median follow-up was 61.6 months. Fifteen percent (33/219) of the 70-gene signature low-risk patients received adjuvant chemotherapy (ACT) versus 81% (169/208) of the 70-gene signature high-risk patients. The 5-year DRFI probabilities for 70-gene signature low-risk (n = 219) and high-risk (n = 208) patients were 97.0% and 91.7%. The 5-year DRFI probabilities for AOL low-risk (n = 132) and high-risk (n = 295) patients were 96.7% and 93.4%. For 70-gene signature low-risk-AOL high-risk patients (n = 124), of whom 76% (n = 94) had not received ACT, 5-year DRFI was 98.4%. In the AOL high-risk group, 32% (94/295) less patients would be eligible to receive ACT if the 70-gene signature was used. In this prospective community-based observational study, the 5-year DRFI probabilities confirmed the additional prognostic value of the 70-gene signature to clinicopathological risk estimations such as AOL. Omission of adjuvant chemotherapy as judged appropriate by doctors and patients and instigated by a low-risk 70-gene signature result, appeared not to compromise outcome. What's new? The "MammaPrint" is a 70-gene signature developed to predict the risk of breast cancer metastases. This study, the RASTER study, provides the first prospective data looking at this 70-gene signature to evaluate it's performance. For 427 patients, treatment decisions were based on standard guidelines, the 70-gene signature, and doctors' and patients' preferences. Here, 124 patients were categorized as "low-risk" by the 70-gene signature, but high-risk by other measures, such as age, tumor size, nodal status, and other clinicopathological factors. Of these, 76% did not receive adjuvant chemotherapy, and 98% survived 5 years with no recurrence of disease. Thus, withholding chemotherapy based on the low-risk gene signature result, and in accordance with doctors' and patients' preferences, did not negatively impact recurrence rate, confirming the prognostic value of this new tool.

Originele taal-2Engels
Pagina's (van-tot)929-936
Aantal pagina's8
TijdschriftInternational Journal of Cancer
Nummer van het tijdschrift4
StatusGepubliceerd - 15 aug. 2013
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study'. Samen vormen ze een unieke vingerafdruk.

Citeer dit